Dallas, Texas 07/12/2013 (Financialstrend) – Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) generated successful results in the trials of its PENNVAX(®)-B preventive HIV DNA vaccine conducted by the company. The trials included two phases, namely HVTN 070 and HVTN 080 which are discharged with DNA adjuvant through the CELLECTRA electoration delivery device of Inovio Pharmaceuticals, Inc. The trials showed that responses in humans for CD4 CD8 T-cell produced through the vaccine were durable and strong. CD4 CD8 T-cell plays a vital role in improving cellular immunity, given that especially the CD8 T fights against chronic infectious diseases and cancer. The PENNVAX(®)-B vaccine of Inovio Pharmaceuticals, Inc. successfully produced a robust CD8 T-cell response which was previously a great challenge for HIV researchers.
Inovio Pharmaceuticals, Inc. recently achieved 100% successful result for the DNA vaccine, which prevents animals from getting infected by the emerging flu named H7N9 virus. The study of DNA vaccine influenza was conducted on mice samples and results turned out positive when they were subject to a dosage that was lethal for the H7N9 virus. All of the samples reported were effectively protected from H7N9 flu virus which causes sickness and death. In addition to the protection from infection, the vaccine also produced strong t-cell results in the samples during the study.
Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) closed at $1.30 on Thursday, recording a decline of 11.56 % in the share price for the day. The stock price fluctuated from a low value of $1.17 to a high one of $1.48 per share. The company currently has a 52-week low of $0.44 and a 52-week high of $1.57 per share.
Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) currently has 179.92 million outstanding shares in the market with institutional ownership of 12% of its total equity capital. Trading volume stood at 20.75 million shares on Thursday, with an average one of 3.59 million shares per day.